Literature DB >> 10623673

Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.

M Losa1, R L Barzaghi, P Mortini, A Franzin, F Mangili, M R Terreni, M Giovanelli.   

Abstract

We investigated the growth fraction and cell loss fraction in a large group of patients with Cushing's disease subdivided according to tumor size. Fifty-one patients, 8 males and 43 females, aged 12 through 61 years (mean age 34.6 +/- 1.5 years), were studied. Thirty-six patients had a microadenoma and the remaining 15 a macroadenoma. Immunohistochemical analysis was performed on paraffin-embedded material using a monoclonal antibody (MIB-1) directed against a proliferation-associated nuclear antigen, Ki-67, to measure the growth fraction. Apoptosis was assessed by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method, using a monoclonal antibody recognizing areas of DNA fragmentation. Ki-67 labeling index and apoptosis were counted on separate slides in at least 1000 evaluable cells. Patients with a macroadenoma had a significantly higher value of Ki-67 index (9.3 +/- 2.7%) than patients with microadenoma (2.8 +/- 0.5%; P < 0.002), whereas the apoptotic index was not significantly different in the two groups (1.7 +/- 0.8% in macroadenomas versus 0.8 +/- 0.3% in microadenomas). Our study shows that ACTH-secreting macroadenomas are characterized by a higher cell growth fraction than microadenomas, whereas the cell loss fraction is not different. A high proliferation rate seems to play a major role in determining the progression from small to large pituitary tumors in Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623673      PMCID: PMC1868637          DOI: 10.1016/S0002-9440(10)64725-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts.

Authors:  M Shibuya; F Saito; T Miwa; R L Davis; C B Wilson; T Hoshino
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas.

Authors:  P Selvais; J Donckier; M Buysschaert; D Maiter
Journal:  Eur J Endocrinol       Date:  1998-02       Impact factor: 6.664

3.  The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour.

Authors:  J G Klijn; S W Lamberts; F H de Jong; R Docter; K J Van Dongen; J C Birkenhäger
Journal:  Clin Endocrinol (Oxf)       Date:  1980-04       Impact factor: 3.478

4.  Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients.

Authors:  J G Klijn; S W Lamberts; F H de Jong; K J van Dongen; J C Birkenhäger
Journal:  Acta Endocrinol (Copenh)       Date:  1980-11

5.  The biology of cell death in tumours.

Authors:  A H Wyllie
Journal:  Anticancer Res       Date:  1985 Jan-Feb       Impact factor: 2.480

6.  Transsphenoidal microsurgery for Cushing disease. A report of 216 cases.

Authors:  T J Mampalam; J B Tyrrell; C B Wilson
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

7.  Cushing's disease: a correlation of radiological, surgical and pathological findings with therapeutic results.

Authors:  F Robert; J Hardy
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

8.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  Am J Clin Pathol       Date:  1981-06       Impact factor: 2.493

Review 9.  Cushing's syndrome: problems in management.

Authors:  D C Aron; J W Findling; P A Fitzgerald; P H Forsham; C B Wilson; J B Tyrrell
Journal:  Endocr Rev       Date:  1982       Impact factor: 19.871

10.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  22 in total

1.  Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece.

Authors: 
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

3.  Cushing's disease due to somatic USP8 mutations: a systematic review and meta-analysis.

Authors:  Ingrid Quevedo Wanichi; Beatriz Marinho de Paula Mariani; Fernando Pereira Frassetto; Sheila Aparecida Coelho Siqueira; Nina Rosa de Castro Musolino; Malebranche Berardo Carneiro Cunha-Neto; Gilberto Ochman; Valter Angelo Sperling Cescato; Marcio Carlos Machado; Ericka Barbosa Trarbach; Marcello Delano Bronstein; Maria Candida Barisson Villares Fragoso
Journal:  Pituitary       Date:  2019-08       Impact factor: 4.107

4.  Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing's disease harbouring microadenomas or macroadenomas.

Authors:  M C Machado; A E E Alcantara; A C L Pereira; V A S Cescato; N R Castro Musolino; B B de Mendonça; M D Bronstein; M C B V Fragoso
Journal:  J Endocrinol Invest       Date:  2016-06-30       Impact factor: 4.256

5.  Factors influencing improvement of visual field after trans-sphenoidal resection of pituitary macroadenomas: a retrospective cohort study.

Authors:  Fen-Fen Yu; Li-Li Chen; Yi-Hua Su; Li-Hun Huo; Xian-Xuan Lin; Rui-Duan Liao
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

6.  Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas.

Authors:  Demetrios Sambaziotis; Nikiforos Kapranos; George Kontogeorgos
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

7.  Different levels of various glucocorticoid-regulated genes in corticotroph adenomas.

Authors:  Johan Arild Evang; Jens Bollerslev; Olivera Casar-Borota; Tove Lekva; Jon Ramm-Pettersen; Jens Petter Berg
Journal:  Endocrine       Date:  2013-01-13       Impact factor: 3.633

8.  Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma.

Authors:  M Losa; A Vimercati; S Acerno; R L Barzaghi; P Mortini; F Mangili; M R Terreni; G Santambrogio; M Giovanelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

9.  Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.

Authors:  E Macchia; M Gasperi; M Lombardi; L Morselli; A Pinchera; G Acerbi; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

10.  ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.

Authors:  Masanori Suzuki; Noboru Egashira; Hanako Kajiya; Takeo Minematsu; Susumu Takekoshi; Shigeyuki Tahara; Naoko Sanno; Akira Teramoto; Robert Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.